Coherus Oncology, Inc. 8-K

What Happened
Coherus Oncology, Inc. filed an 8-K on January 23, 2026 to disclose a prospectus supplement under its Sales Agreement (originally dated November 8, 2022, with subsequent amendments) that allows the company to offer and sell, from time to time, up to $64,880,054 aggregate offering price of its common stock through TD Securities (USA) LLC (TD Cowen). The shares are common stock, par value $0.0001 per share. The company also filed a legal opinion from Latham & Watkins LLP regarding the validity of the issuance and sale (Exhibit 5.1).

Key Details

• Prospectus supplement filed: January 23, 2026.
• Sales Agreement history: original Nov 8, 2022; amended May 15, 2023 and Sept 11, 2023; assigned to TD Securities (USA) LLC.
• Offering capacity: up to $64,880,054 aggregate offering price of common stock, sold from time to time through TD Cowen.
• Legal documentation: opinion of Latham & Watkins LLP included as Exhibit 5.1 (consent included as Exhibit 23.1).

Why It Matters
This filing gives Coherus flexibility to raise capital by selling shares into the market up to the stated dollar amount. For investors, that means potential future dilution if the company actually issues shares under this program, but also increased access to funding without needing a separate registered offering. The inclusion of a legal opinion addresses the formal validity of the planned issuance.